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A B S T R A C T
Interferon-γ-based assays, collectively known as IFN-γ release assays (IGRAs), have emerged as a reliable 
alternative to the old tuberculin skin test (TST) for the immunodiagnosis of tuberculosis (TB) infection. The 
2 commercially available tests, the enzyme-linked immunosorbent assay (ELISA), QuantiFERON-TB Gold In-
tube (QFT-IT), and the enzyme-linked immunospot assay (ELISPOT), T-SPOT.TB, are more accurate than TST 
for the diagnosis of TB, since they are highly specific and correlate better with the existence of risk factors 
for the infection. According to the available data, T-SPOT.TB obtains a higher number of positive results 
than QFT-IT, while its specificity is lower. Although the sensitivity of the IFN-γ -based assays may be 
impaired to some extent by cellular immunosuppression and extreme ages of life, they perform better than 
TST in these situations. Data from longitudinal studies suggest that IFN-γ-based tests are better predictors 
of subsequent development of active TB than TST; however this prognostic value has not been consistently 
demonstrated. This review focuses on the clinical use of the IFN-γ -based tests in different risk TB groups, 
and notes the main limitations and areas for future development. 
Diagnóstico de la tuberculosis mediante las técnicas basadas en la detección de 
interferón-γ
R E S U M E N
Las técnicas de detección de la liberación de interferón-γ conocidas como IFN-γ release assays (IGRA), cons-
tituyen una alternativa fiable a la clásica prueba de la tuberculina (PT) para el inmunodiagnóstico de la in-
fección tuberculosa. Las 2 pruebas comerciales disponibles, QuantiFERON-TB Gold In-tube (QFT-IT) y T-
SPOT.TB, son más precisas que la PT para el diagnóstico de tuberculosis (TB), ya que son muy específicas y 
presentan una mejor correlación con la existencia de factores de riesgo para la infección tuberculosa. Según 
los datos disponibles, T-SPOT.TB detecta mayor número de positivos que QFT-IT, pero es menos específica. 
Aunque en determinadas situaciones, como en pacientes con inmunosupresión celular y en las edades ex-
tremas de la vida, estas técnicas siguen siendo superiores a la PT. Estudios longitudinales sugieren que las 
pruebas de liberación de IFN-γ son mejores predictores de la progresión a enfermedad tuberculosa; sin 
embargo, este hecho no ha sido demostrado completamente. Esta revisión trata el uso de los test de libera-
ción de IFN-γ en diferentes grupos de riesgo de TB. Asimismo, remarca sus principales limitaciones y las 
áreas de desarrollo futuro. 
*Corresponding author.
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From the tuberculin skin test to the interferon-γ-based assays
The tuberculin skin test (TST), that recalls the delayed-type 
hypersensitivity response to the intradermal inoculation of purified 
protein derivate (PPD),1 has been used to diagnose TB infection for 
the last hundred years. The PPD contains a mixture of more than 200 
antigens that are widely shared by mycobacteria other than 
Mycobacterium tuberculosis, including the vaccinal strain of 
Mycobacterium bovis bacilli Calmette-Guérin (BCG) and many non-
tuberculous mycobacteria (NTM). As a result, individuals sensitized 
by previous exposure to NTM or BCG vaccine may respond 
immunologically to PPD. The other main limitation of the TST is its 
low sensitivity in certain groups of individuals, such as 
immunosuppressed patients and young children.2
Immunodiagnostic methods have been developed based on the in 
vitro quantification of the cellular immune response, by detecting 
interferon-gamma (IFN-γ) released by sensitized T-cells stimulated 
with specific M. tuberculosis antigens. The two main antigens used 
are the 6-kD M. tuberculosis early-secreted antigenic target protein 
(ESAT-6) and the 10-kD culture filtrate protein (CFP-10), encoded in 
the region of difference 1 (RD1), which is present in M. tuberculosis 
but not in BCG or in most NTM.3 This new in vitro technology has 
been rapidly adapted from initial in-house methods to the two 
commercially available techniques: QuantiFERON-TB Gold assays 
(QFT-G) (Cellestis Limited, Carnegie, Victoria, Australia) and T-SPOT.
TB assay (Oxford Immunotec, Oxford, UK). Both tests, collectively 
known as IGRAs (Interferon-Gamma Release Assays), have been 
approved for sale in Europe and have received final approval from 
the U.S. Food and Drug Administration (FDA) as an aid for diagnosing 
M. tuberculosis infection. T-SPOT.TB detects the number of IFN-γ 
producing T-cells after stimulating a definite number of isolated 
peripheral blood mononuclear cells (PBMCs) with ESAT-6 and CFP-10 
separately by means of enzyme-linked immunospot assay (ELISPOT). 
QFT-G tests are whole blood assays that use an enzyme-linked 
immunosorbent assay (ELISA) to detect IFN-γ produced in 
supernatants by stimulated T-cells. The QFT-G In Tube version (QFT-
IT), includes a third antigen, TB7.7. This new antigen is encoded in 
RD11 and is missing from the BCG strains as well as most common 
environmental mycobacteria.4 In the QFT-IT assay, the three specific 
M. tuberculosis antigens are already incorporated into the same tube 
(Fig. 1). Both in vitro tests include a positive control that detects the 
capacity of T cells to produce IFN-γ upon stimulation with a mitogen 
(phytohemagglutinin), in order to distinguish false-negatives from 
indeterminate results. 
Interferon-γ-based assays for detecting latent infection in 
high-risk populations
This section will discuss the potential value of the IFN-γ-based 
tests in diagnosing latent TB infection (LTBI) in people at high risk of 
progression to active disease. 
Contact tracing study
Between 5% and 10% of recently infected contacts will develop 
active TB within 2-5 years after exposure. The identification and 
treatment of these individuals constitutes an essential component of 
the TB control strategy in low-prevalence countries. Numerous 
studies have explored the utility of the IFN-γ-based tests in contact 
investigations.5-9 In the absence of a gold standard test for the 
diagnosis of LTBI, the best approach to compare IFN-γ-based tests 
and TST consists of correlating their results with the degree of 
exposure to an infectious case. Positive results of IFN-γ-based tests 
were found to be more strongly associated with greater recent 
exposure than TST;5,8 however, this association could not be 
demonstrated by others.9 Besides, IFN-γ-based tests offer the 
advantage of high specificity, since they are not affected by prior BCG 
vaccination or by infection with most NTM.
Health care workers
Due to the risk of infection with M. tuberculosis through 
occupational exposure, periodical testing is recommended for all 
health care workers (HCWs). Serial TST testing may induce a boosting 
phenomenon, compromising its interpretation.10 In a study performed 
in Barcelona (Spain),11 prevalence of LTBI in HCWs without a previous 
positive TST was higher according to T-SPOT.TB (23.1%), and QFT-IT 
(17.3%) than according to TST (15.4%). Positive IFN-γ tests were 
associated with age and degree of occupational exposure, but not 
with BCG vaccination, a finding consistent with previous studies 
with QFT-G tests.12,13 Although IFN-γ-based tests have became a good 
alternative to TST for serial testing of HCWs, factors such as reversions 
and conversions should be taken into account. Choi et al14 described 
conversions of QFT-IT in HCWs 2-4 weeks after performing a TST test 
among TST reactors, but not among non-reactive individuals. 
Similarly, van Zyl-Smit et al15 reported conversions a week after TST 
administration. However, when using a two-step screening strategy, 
IFN-γ test results were not influenced if TST was performed within 
three days.
Immunocompromised patients
The performance of the IFN-γ tests in immunocompromised 
patients and the effect of immunosuppression on these tests remains 
unclear.16 Previous studies including different groups of 
immunocompromised patients found impaired performance of IFN-
γ-based tests related to malfunction of cellular immune system, but 
they performed better than TST nonetheless.17,18 In a prospective 
study including 369 immunosuppressed participants, Richeldi et al19 
found that IFN-γ tests detected more patients as being infected with 
M. tuberculosis than did TST.
HIV infected patients
Patients co-infected with HIV and M. tuberculosis are particularly 
prone to a reactivation of LTBI and development of disseminated 
disease. In studies evaluating T-SPOT.TB and its ELISPOT pre-
commercial version20,21 or the QFT-G tests,22,23 in vitro tests obtained 
higher rates of positive results than TST in diagnosing LTBI,23,24 and a 
better association between positive results and presence of risk 
factors for LTBI.22,23 In recent years, some studies in HIV-infected 
populations reported similar sensitivities for both IFN-γ tests.21-25 As 
regards indeterminate results, a correlation between low CD4+ cell 
counts and a low control positive response was found with QFT-IT,22 
while T-SPOT.TB and in-house ELISPOT appeared to be relatively 
unimpaired by low CD4+ cell counts.24,26,27 However, higher rates of 
indeterminate results with T-SPOT.TB and in-house ELISPOT have also 
been reported.24,28
Chronic immune-mediated inflammatory disease 
Tumor necrosis factor (TNF)-α antagonists provide reliable 
treatment in patients with immune-mediated inflammatory diseases 
(IMID).29 TNF-α is one of the key molecules involved in granuloma 
formation and containment of TB infection. Due to the increased risk 
of TB in patients receiving anti-TNF-α agents,30 exclusion of active TB 
and screening for latent infection is mandatory before starting anti-
TNF-α therapy.31 However, cellular-mediated response to PPD is 
compromised by the corticosteroids and/or immunosuppressive 
drugs that most patients with IMID are already taking.29,31 Experience 
with the IFN-γ-based tests in this population, although promising, is 
still limited.32,33 Overall, agreement with the TST seems to be poor.34-
36 The discordant positive TST and negative IFN-γ-based test results 
have been attributed to false-positive TST results,37,38 whereas the 
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discordant negative TST and positive IFN-γ-based test results have 
been considered false-negative TST results due to the 
immunosuppressive therapy being taken by these patients.35,36,39 The 
available data show that the IFN-γ-based tests detect more cases of 
LTBI than TST does,36,40 and a closer association with the presence of 
risk factors for TB infection.34,35 The effect of DMID-associated 
immunosuppression on the performance of the IFN-γ-based tests has 
not been completely clarified. In a study involving 398 consecutive 
subjects, Bartalesi et al41 did not find an association between results 
of the TST or QFT-IT and the use of conventional disease-modifying 
antirheumatic drugs, but reported an association of steroids with a 
lower likelihood of a positive result. In view of the high risk of TB in 
IMID patients receiving anti-TNF-α therapy, a strategy based on a 
simultaneous TST and one of the IFN-γ tests might maximize 
diagnostic sensitivity for the detection of LTBI. 
Paediatric population
Children have a high risk of progression to active TB, especially 
infants under the age of two.42 Early, specific diagnosis of LTBI is 
therefore crucial to prevent active disease. The sensitivity of TST in 
young children is unknown, but the existence of immaturity certainly 
induces a lower cutaneous response. In addition, BCG-vaccination, 
especially in TB endemic areas, reduces the test’s specificity. Overall, 
T-SPOT.TB provides higher rates of positive results for LTBI than TST 
or the QFT-G tests. Recently, Davies et al43 found that, in contrast to 
TST, ELISPOT results were not affected by young age or severe 
immunosuppression. Furthermore, a high correlation with the 
degree of exposure to M. tuberculosis with both IFN-γ-based tests has 
been demonstrated.44 Results of both IFN-γ-based tests are unrelated 
to the BCG-vaccination status, which contributes to their high 
specificity.4,7 Discordant results between these tests and TST are 
frequently found.7,45-48 In a study conducted in Barcelona (Spain),7 
among BCG-unvaccinated children, 60% and 57% of those with 
positive TST had negative QF-IT and T-SPOT.TB respectively. Latorre 
et al49 reported that 48% of children with TST positive and negative 
T-SPOT.TB had sensitized T cells against Mycobacterium avium 
sensitins. As regards the indeterminate results, a significantly lower 
IFN-γ release in response to mitogen (positive control) has been 
described in young children tested with QFT-IT, suggesting an age-
dependent response.47,50 As for T-SPOT.TB, it does not seem to be 
related to age,17 except in the first weeks of life.51 However, Nicol et 
al48 reported a decline in positive T-SPOT.TB results in children less 
than 1 year of age, whereas TST results were unaffected.
Interferon-γ-based assays for diagnosing active tuberculosis
Although the IFN-γ-based tests are widely used together with or 
in place of TST, their role in the diagnosis of active disease is still 
undefined. According to the results of two recent meta-analyses,52,53 
both commercial IFN-γ-based tests, performed in blood, have better 
sensitivity than TST for active TB. As expected, specificity for active 
disease was low, ranging from 59% for T-SPOT.TB to 79% for QFT-IT 
and 75% for TST.53
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Figure 1. Comparison of T-SPOT.TB and QuantiFERON-TB Gold In Tube (QFT-IT) methodology. ELISA: enzyme-linked immunosorbent assay; ELISPOT: enzyme-linked immunospot 
assay; IFN: interferon; PBMCs: peripheral blood mononuclear cells.
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While a positive result of an IFN-γ-based assay does not distinguish 
between active and latent infection, in combination with the TST 
result it may help to exclude active TB.54-56 A recent multicentre 
study55 showed a very low likelihood of TB with a negative result on 
both TST and IFN-γ-based tests. Unfortunately, only 4% of patients 
were immunosuppressed, which precludes its generalization to the 
whole risk population. The usefulness of levels of IFN-γ, measured by 
QFT-IT, to predict clinical outcome was evaluated in two studies.56,57 
Although active TB was associated with higher IFN-γ levels, the 
benefit was presumed to be marginal in highly experienced centres. 
Cellular immunosuppression and age, among other factors, may 
impair performance of IFN-γ-based tests.58 In 4 studies that compared 
performance of QFT-IT in HIV-infected and non-infected adults with 
active TB, mean sensitivity was 64% in HIV-infected patients and 79% 
in non-HIV-infected patients.59-62 Although the overall sensitivity of 
T-SPOT.TB is higher than that of QFT-IT in otherwise healthy people, 
data from head-to-head comparisons in HIV-infected patients are 
scarce.60,63,64 In three studies, covering a total of 39 patients with 
culture-confirmed TB, QFT-IT and T-SPOT.TB detected 74% and 82% of 
cases respectively.60,64 Despite impaired sensitivity, IFN-γ-based tests 
are clearly superior to TST for the diagnosis of active TB in these 
patients.61,65-67
IFN-γ-based tests may be of value in diagnosing TB in childhood, 
due to the absence of microbiological confirmation in a high 
proportion of cases. In a large prospective study, the sensitivity of 
T-SPOT.TB was 83%, and was not affected by HIV status.20 A hospital-
based study reported sensitivity rates of 100% for TST and 73% for 
T-SPOT.TB and QFT.IT, and specificity rates of 58%, 98% and 100% for 
TST, T-SPOT.TB and QFT-IT respectively.68 A multicentre study 
comparing both IFN-γ-based tests with TST in 333 children aged 2 
months to 16 years found that in 49 TB-confirmed cases, sensitivity 
was 82% for TST, 78% for QFT-IT and 66% for T-SPOT.TB, increasing to 
96% and 91% when TST was combined with T-SPOT and QFT-IT 
respectively.69
As regards aged patients, the data available show that QFT-G is 
more sensitive than TST in patients older than 80 years with active 
TB.70,71 Although the sensitivity of QFT-G decreased with age, it 
remained better than that of TST.71,72
Interferon-γ-based assays in fluids other than blood 
IFN-gamma is predominantly produced by effector T-cells. The 
recruitment of specific T cells during active TB and the process via 
which antigen-specific cells clonally expand and migrate to the site 
of infection have been described.73 Therefore, during active TB, it 
makes sense to apply IFN-based assays in samples collected directly 
from the site of infection. Data from a recent metanalysis53 indicate 
that the T-SPOT.TB assay in extrasanguineous fluids is a promising 
tool for the diagnosis of active TB.
Pulmonary tuberculosis
 Rapid diagnosis of pulmonary TB relies on the detection of acid-
fast bacilli (AFB). However, this can be difficult due to the low 
sensitivity of the sputum smear. In addition, a significant proportion 
of cases cannot be confirmed by culture. In a prospective study by 
Jafari et al,74 all 12 patients with smear-negative pulmonary TB, but 
none of the 25 controls, had positive T-SPOT.TB test from the 
bronchoalveolar lavage (BAL). TB-specific T cells were more 
concentrated in BAL than in peripheral blood, indicating a highly 
selective compartmentalization at the site of infection.75 A recent 
large study carried out by the TBNET confirmed the high sensitivity, 
specificity and predictive values of T-SPOT.TB from the BAL.76
Pleural tuberculosis
The diagnosis of pleural TB is often difficult due to the limitations 
of conventional tests.77 Wilkinson et al73 found a 15-fold greater 
concentration of ESAT-6-specific spot-forming T cells in pleural fluid 
than of PBMCs in 10 patients with pleural TB. These cells were not 
found in the pleural fluid of 8 patients with nontuberculous pleuritis.73 
In a TBNET study,78 T-SPOT.TB was performed on mononuclear cells 
from blood and pleural fluid in 20 patients with pleural TB and in 21 
with pleural effusion of other causes. T-SPOT.TB was positive in 90% 
of cases on blood samples and in 95% of cases pleural fluid. Specificity 
was 67% for blood and 76% for pleural fluid. In another study of 28 
patients with pleural TB, results in pleural fluid were inconclusive in 
52% of cases, due to high background IFN-γ production.79 Commercial 
IFN-γ tests, T-SPOT.TB and QFT-IT in pleural fluid were compared to 
unstimulated IFN-γ for the diagnosis of pleural TB in 74 patients.80 In 
11 (15%) cases, the cell counts were not large enough to perform the 
tests. In the 63 remaining patients, sensitivity, specificity, positive 
predictive value and negative predictive value were: for T-SPOT.TB, 
86, 60, 84 and 64% respectively; for QFT-IT, 57, 80, 87 and 44% 
respectively, and for unstimulated IFN-γ, 97, 100, 100 and 94% 
respectively. The authors concluded that the IFN-γ-based assays had 
suboptimal accuracy for the diagnosis of pleural TB.
Tuberculous meningitis
Tuberculous meningitis (TBM) is a challenge for clinicians because 
of the frequent absence of microbiological confirmation and high 
mortality if not promptly treated. In one study including 10 patients 
with a diagnosis of TBM, T-SPOT.TB detected M. tuberculosis antigen-
specific IFN-γ in CSF from nine patients (90%), but in none of the seven 
controls (specificity 100%).81 In a study with 12 patients with TB of the 
central nervous system and 25 without TB, T-SPOT’s sensitivity and 
specificity in CSF were 75%.82 Recently, in a prospective observational 
study of 31 patients with confirmed or probable TBM, the same group 
of investigators83 reported a sensitivity of 59% and a specificity of 89% 
for T-SPOT.TB in CSF mononuclear cells. However, since the diagnosis 
was not confirmed microbiologically in 21 of these patients, the 
sensitivity may have been underestimated. Similarly, in a study of 140 
patients with meningitis (81% HIV-infected), using ≥46 spot-forming 
cells as cut-off point and after excluding bacterial and cryptococcal 
meningitis, the positive and negative predictive values of T-SPOT.TB in 
CSF were 100% and 68% respectively.84
Interferon-γ-based assays for predicting subsequent active 
tuberculosis
The ability to predict subsequent active TB among latently infected 
people is essential in order to select those who would benefit from 
chemoprophylaxis and to avoid unnecessary treatment for low-risk 
persons. Doherty et al85 demonstrated a strong association of 
reactivity to ESAT-6 and progression to active TB in twenty-four 
household contacts of smear-positive TB patients. In a study involving 
601 close contacts of sputum smear-positive TB, Diel et al86 found 
that while 14.6% of contacts with positive QFT-IT who declined 
treatment developed TB within the 2-year follow-up, only 2.3% of 
those with positive TST did. This difference between TST and QFT-IT 
disappeared when only unvaccinated contacts were considered.87 
More recently, the same group of investigators88 extended the 
original study and reported progression to active TB for up to four 
years for a cohort of 954 close contacts of smear-positive index cases. 
Of 147 untreated contacts with a positive QFT-IT test 19 (12.9%) 
developed active TB, whereas only 17 of 155 (3.1%) with TST >5 mm 
did. The progression rate was higher among children (28.6%). In 
addition, none of 824 untreated contacts with negative QFT-IT 
developed active TB, confirming the high negative predictive value of 
the test.88 In the study by Kik et al89 of 339 close contacts of sputum 
smear-positive TB, TST, QFT-IT and T-SPOT.TB were comparable in 
predicting development of TB during a two-year period. Positive 
predictive values were 3.1% for TST ≥10 mm, 3.8% for TST ≥15 mm, 
2.8% for positive QFT-IT and 3.3% for T-SPOT.TB. In a cohort of 308 
 M Santín Cerezales et al / Enferm Infecc Microbiol Clin. 2011;29(Supl 3):25-32 29
silicosis patients, Leung et al87 found that a positive T-SPOT.TB 
significantly predicted development of active TB during a follow-up 
of more than 2 years (RR 7.80; 95%CI 1.02-59.6). Unexpectedly, TST 
was not predictive of TB, regardless of the cut-off point used. In a 
study with 2348 household contacts in Gambia, Hill et al90 found that 
neither the TST nor the T-SPOT.TB predicted development of TB. The 
lack of predictive value was attributed to the high-burden of TB and 
recent transmission.
Two studies assessed QFT-IT and progression to active disease in 
HIV-seropositive individuals.91,92 In a large study in a low-prevalence 
country, 8.1% of HIV-seropositive patients with a positive QFT-IT 
result at baseline, and left untreated, developed TB during a median 
follow-up of 19 months. None of the 738 patients with negative 
results had TB.91 In a study in Spain of 135 HIV-infected individuals 
without active disease, none of the 103 patients who had a negative 
or indeterminate QFT-IT result at baseline had TB after a median 
follow-up of 20 months.92
Development of TB was also assessed in child and adolescent 
contacts. Bakir et al93 studied 908 children with recent household 
exposure to TB, most of whom received preventive therapy. During a 
follow-up of 1.3 years, children with positive T-SPOT.TB had a 3- to 
4-fold higher risk of developing active TB than those with negative 
T-SPOT.TB. However, rates of progression were similar in children 
with positive T-SPOT.TB and TST reactors. Since a high proportion of 
children were treated, the true incidence rates may have been 
underestimated. In the study by Higuchi et al,94 349 students 
underwent QFT-G and TST simultaneously, but only those with 
positive QFT-G were given chemoprophylaxis. Follow-up of the 91 
students with positive TST but negative QFT-G showed no cases of 
active TB.
Although IFN-γ-based tests seem to predict subsequent active TB 
better than TST, the majority of high-risk people with positive tests 
will not develop active TB. Conversely, subsequent active TB in the 
next two to three years seems to be extremely low among people 
with a negative result.85-87,89-94 Table 1 summarizes the nine studies 
assessing development of active TB with IFN-γ-based tests.
Final remarks and areas of future development
IFN-γ-based assays have become a reliable alternative to the old 
TST for the diagnosis of TB infection. Both commercial tests, QFT-IT 
and T-SPOT.TB, have a higher specificity than TST, and a better 
correlation with risk factors for TB and the degree of contact with an 
infectious case. Although their sensitivity may be affected to some 
extent by immunosuppression and extreme ages of life, they perform 
better than TST in these situations. Besides, IFN-γ-based tests do not 
induce boosting, and no additional visits are required for reading.
A great deal is now known about IFN-γ-based assays, and their 
use has expanded considerably. However, the prognostic value of a 
positive/negative result for the development of active TB, the 
significance of discordant results, the cut-off points to use in 
immunosuppressed people, the conversion/reversion phenomenon, 
and their role in the diagnosis of paucibacillary forms of TB, are some 
of the important questions that remain unresolved. 
Table 1
Summary of 9 studies evaluating the predictive value of the interferon-γ based tests for the development of tuberculosis 
Study (reference) Country Study population
Period of 
follow-up 
(years)
Test Positive test n/N (%) Sensitivity (%) Specificity (%) PPV (%) NPV (%)
Doherty et al85 Ethiopia Household contact 
adults
2 ELISA (PPD) 21/24 (88) 100 18 33 100
ELISA 
(ESAT-6)
9/24 (38) 86 83 67 93
Leung et al87 Hong Kong Silicosis patients 2.5a TST (10 mm) 203/308 (66) 77 35 6.4 96
T-SPOT.TB 204/308 (66) 88 36 7.4 98
Diel et al88 Germany Close contact adults 4 TST 555/903 (60) 89 61 3.1 99
QFT-IT 147/903 (16) 100 86 12.9 100
Kik et al89 Netherlands Contact immigrant 
adults
2 TST 339b 100 16 3.1 100
QFT-IT 178/324 (55)b 63 45 2.8 98
T-SPOT.TB 181/299 (61)b 75 40 3.3 98
Hill et al90 Gambia Household contact 
childre & adults 
2 TST 843/2230 (38) 54 62 1.7 99
(HIV +ve and -ve) T-SPOT.TB 649/1736 (37) 42 63 1.7 99
Aichelburg et al91 Austria HIV (+) adults 1.6 QFT-IT 44/783 (5.6) 100 95 8.1 100
Santin et al92 Spain HIV (+) adults 1.6a TST 7/120 (6) – 94c – 100c
QFT-IT 13/120 (11) – 89c – 100c
Bakir et al93 Turkey Contact children 1.3 TST 550/908 (61) 80 40 2 99
T-SPOT.TB 381/908 (42) 73 59 3 99
Higuchi et al94 Japan Contact adolescents 3.5 TST 95 – 73 – 100
QFT-G 4/88d – 96e – 100e
NPV: negative predictive value; PPV: positive predictive value.
 aMean follow-up.
 bOnly subjects with positive TST were tested with QFT-IT and T-SPOT.TB.
 cCalculated with 120 non-treated patients (those with negative TST and negative/indeterminate QFT-IT).
 dOnly subjects with positive TST were tested with QFT-G.
 eCalculated with 84 non-treated subjects (those with negative QFT-G).
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The actual prognostic value of a positive IFN-γ result needs to be 
clarified. Although the available data suggest that IFN-γ tests 
predict progression to active disease better than TST, most people 
with a positive result will not develop TB. Large prospective studies 
are urgently needed. Furthermore, the question of whether 
quantification of IFN-γ release may be of help in this situation, as 
has been previously suggested,85,86 should also be addressed. 
Because of the discordance between IFN-γ tests and TST results, 
practitioners are reluctant to use them in everyday clinical practice. 
Trials focusing specifically on understanding the discordant results 
between IFN-γ tests and the TST, and between IFN-γ tests 
themselves, are required. This issue is especially relevant in 
childhood, where the effect of NTM infection may play an important 
role.49 Since in vitro assays rely on the secretion of IFN-γ, which is 
largely produced by CD4+ T cells, determining the CD4 threshold at 
which the performance of these assays declines is of particular 
importance. In addition, studies exploring the effect of the different 
immunosuppressor drugs on the response, as well as the accuracy 
of new cut-offs for diagnosing LTBI in immunosuppressed patients, 
are needed. Detection of M. tuberculosis specific T cells in samples 
other than blood with ELISPOT is a promising tool for the diagnosis 
of smear-negative pulmonary TB76 and other paucibacillary forms 
of TB.78,81 The methodological procedures and appropriate cut-offs 
should be established. 
While awaiting answers to these questions, the use of the IFN-γ-
based tests in clinical practice should be guided by clinical judgement 
and evidence-based guidelines for different groups of patients must 
be developed. 
Finally, technical modifications of IFN-γ-based tests are being 
explored.95 The attempts to improve IFN-γ-based tests include the 
study of alternative readouts to measure IFN-γ release.95,96 the use of 
alternative M. tuberculosis specific antigens,4,97 and the simultaneous 
measurement of chemokines98 and interleukins.99 The next generation 
of IFN-γ-based tests will significantly enhance diagnostic sensitivity 
without diminishing specificity, and will also reduce the rate of 
indeterminate results, especially in immunosuppressed patients and 
children. 
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